Tags

Type your tag names separated by a space and hit enter

Prevention of influenza by the intranasal administration of cold-recombinant, live-attenuated influenza virus vaccine: importance of interferon-gamma production and local IgA response.

Abstract

To clarify which immunological factors were more effective in preventing influenza virus infection, we measured immunological parameters induced by vaccination and infection in vivo and in vitro. Healthy adult subjects (n = 128) were divided into vaccinated (n = 85) and untreated (n = 43) groups. Eighty-five were vaccinated intranasally with a trivalent cold-adapted recombinant influenza virus vaccine containing type A (H1N1 and H3N2) and B viruses. Subjects were mostly seropositive before vaccination. In 29 (80.6%) of the 36 examinees showing a prevaccination HI antibody titre of less than 1:128, the titre increased more than four times after vaccination. On the other hand, an increase of more than four times was found in four (8.2%) of the 49 individuals who had shown a prevaccination titre of more than 1:128. The IgA antibody was negligibly detected in the nasal wash specimens before vaccination, and was induced by vaccination in some cases. Lymphocyte proliferation and interleukin 2 (IL-2) production in cultured lymphocytes of the same subjects stimulated by H1N1 virus in vitro were correlated with the HI antibody titre. However, the interferon gamma (IFN-gamma) production was low before vaccination, regardless of the HI antibody titre, and showed a significant increase after vaccination. It was suggested that local IgA response and IFN-gamma production play important roles in the prevention of influenza. Since there was the outbreak of influenza A (H1N1) in Kochi Prefecture after completion of blood samples 6-8 weeks after the second vaccination, we examined the above hypothesis.(

ABSTRACT

TRUNCATED AT 250 WORDS)

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Pediatrics, Kochi Medical School, Japan.

    , ,

    Source

    Vaccine 13:2 1995 Feb pg 185-90

    MeSH

    Administration, Intranasal
    Adult
    Disease Outbreaks
    Female
    Humans
    Immunoglobulin A
    Influenza A virus
    Influenza B virus
    Influenza Vaccines
    Influenza, Human
    Interferon-gamma
    Interleukin-2
    Lymphocyte Activation
    Male
    Surveys and Questionnaires
    Vaccines, Attenuated
    Vaccines, Synthetic

    Pub Type(s)

    Clinical Trial
    Journal Article
    Randomized Controlled Trial
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    7625114

    Citation

    Tomoda, T, et al. "Prevention of Influenza By the Intranasal Administration of Cold-recombinant, Live-attenuated Influenza Virus Vaccine: Importance of Interferon-gamma Production and Local IgA Response." Vaccine, vol. 13, no. 2, 1995, pp. 185-90.
    Tomoda T, Morita H, Kurashige T, et al. Prevention of influenza by the intranasal administration of cold-recombinant, live-attenuated influenza virus vaccine: importance of interferon-gamma production and local IgA response. Vaccine. 1995;13(2):185-90.
    Tomoda, T., Morita, H., Kurashige, T., & Maassab, H. F. (1995). Prevention of influenza by the intranasal administration of cold-recombinant, live-attenuated influenza virus vaccine: importance of interferon-gamma production and local IgA response. Vaccine, 13(2), pp. 185-90.
    Tomoda T, et al. Prevention of Influenza By the Intranasal Administration of Cold-recombinant, Live-attenuated Influenza Virus Vaccine: Importance of Interferon-gamma Production and Local IgA Response. Vaccine. 1995;13(2):185-90. PubMed PMID: 7625114.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Prevention of influenza by the intranasal administration of cold-recombinant, live-attenuated influenza virus vaccine: importance of interferon-gamma production and local IgA response. AU - Tomoda,T, AU - Morita,H, AU - Kurashige,T, AU - Maassab,H F, PY - 1995/2/1/pubmed PY - 1995/2/1/medline PY - 1995/2/1/entrez SP - 185 EP - 90 JF - Vaccine JO - Vaccine VL - 13 IS - 2 N2 - To clarify which immunological factors were more effective in preventing influenza virus infection, we measured immunological parameters induced by vaccination and infection in vivo and in vitro. Healthy adult subjects (n = 128) were divided into vaccinated (n = 85) and untreated (n = 43) groups. Eighty-five were vaccinated intranasally with a trivalent cold-adapted recombinant influenza virus vaccine containing type A (H1N1 and H3N2) and B viruses. Subjects were mostly seropositive before vaccination. In 29 (80.6%) of the 36 examinees showing a prevaccination HI antibody titre of less than 1:128, the titre increased more than four times after vaccination. On the other hand, an increase of more than four times was found in four (8.2%) of the 49 individuals who had shown a prevaccination titre of more than 1:128. The IgA antibody was negligibly detected in the nasal wash specimens before vaccination, and was induced by vaccination in some cases. Lymphocyte proliferation and interleukin 2 (IL-2) production in cultured lymphocytes of the same subjects stimulated by H1N1 virus in vitro were correlated with the HI antibody titre. However, the interferon gamma (IFN-gamma) production was low before vaccination, regardless of the HI antibody titre, and showed a significant increase after vaccination. It was suggested that local IgA response and IFN-gamma production play important roles in the prevention of influenza. Since there was the outbreak of influenza A (H1N1) in Kochi Prefecture after completion of blood samples 6-8 weeks after the second vaccination, we examined the above hypothesis.(ABSTRACT TRUNCATED AT 250 WORDS) SN - 0264-410X UR - https://www.unboundmedicine.com/medline/citation/7625114/Prevention_of_influenza_by_the_intranasal_administration_of_cold_recombinant_live_attenuated_influenza_virus_vaccine:_importance_of_interferon_gamma_production_and_local_IgA_response_ L2 - https://linkinghub.elsevier.com/retrieve/pii/0264410X9593134U DB - PRIME DP - Unbound Medicine ER -